This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Natco Pharma Limited. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Bulli Babi Vipparla: Innovator in Pharmaceutical Intermediates
Introduction
Bulli Babi Vipparla is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel intermediates for drug preparation. His work is characterized by a focus on commercially viable processes that can be scaled for industrial applications.
Latest Patents
Bulli Babi Vipparla holds a patent for "Intermediates for the preparation of eribulin thereof." This invention relates to novel intermediates of Eribulin and outlines a process for their preparation. The process described in the patent is not only innovative but also commercially viable, making it suitable for plant-scale operations. The invention focuses on tetrahydrofuran compounds of specific formulas, which are crucial for the synthesis of Eribulin.
Career Highlights
Bulli Babi Vipparla is associated with Natco Pharma Limited, a prominent player in the pharmaceutical industry. His role at the company has allowed him to leverage his expertise in drug development and contribute to the advancement of pharmaceutical sciences. His work has been instrumental in enhancing the efficiency of drug manufacturing processes.
Collaborations
Bulli Babi Vipparla has collaborated with several professionals in his field, including Sreenivas Nagapuri and Sathaiah Kandula. These collaborations have fostered a productive environment for innovation and have contributed to the successful development of new pharmaceutical intermediates.
Conclusion
Bulli Babi Vipparla is a distinguished inventor whose work in pharmaceutical intermediates has the potential to impact drug manufacturing significantly. His innovative approach and collaboration with industry professionals highlight his commitment to advancing pharmaceutical sciences.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
